All Updates

All Updates

icon
Filter
Partnerships
Oncodesign Precision Medicine and Navigo Proteins partner for systemic radiotheranostic agents development
Precision Medicine
May 15, 2024
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
Precision Medicine

Precision Medicine

May 15, 2024

Oncodesign Precision Medicine and Navigo Proteins partner for systemic radiotheranostic agents development

Partnerships

  • Navigo Proteins and Oncodesign Precision Medicine have entered a partnership focusing on the advancement of novel systemic radiotheranostic agents used in cancer treatment.

  • The partnership will leverage OPM's technologies and Navigo's proprietary Affilin platform to develop new treatments for resistant and metastatic cancers. The aim is to create radiotheranostic agents that can detect and destroy tumor cells, a method that's been clinically successful in treating specific types of cancers. The partnership will initially focus on two targets in oncology and develop molecules to the stage of drug candidates. The companies also aim to expand the partnership to additional targets. 

  • Headquartered in Germany, Navigo Proteins is a biotechnology company specializing in protein engineering. Its focus is on developing precision affinity ligands and biotherapeutics. Navigo Proteins uses its proprietary platforms, Precision Capturing and Precision Targeting, to create custom affinity chromatography solutions and novel biotherapeutics, respectively.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.